Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
221 participants
INTERVENTIONAL
2017-07-15
2021-05-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary:
The primary objective is to determine whether the mean weight gain over a 16-week interval starting on or before 14 days of life differs between infants fed one of two infant formulas as their sole source of nutrition: a commercial formula using a canola l fat blend (Control, E23) or the same formula containing the human milk oligosaccharide (Test (HMO) 2-fucosyllactose (2FL). Mean weight gain also will be compared to that of a concurrently enrolled reference group of exclusively breastfed infants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Growth and Tolerance of Infants Fed Milk-Based Infant Formula
NCT03967132
Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants
NCT03214822
Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)
NCT06212427
The Trial of a New Infant Formula in Healthy Term Chinese Infants
NCT06053112
Second Generation Human Milk Oligosaccharides Blend Study
NCT03722550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Infants will be enrolled on or before 14 days of age and fed a study assigned formula for 16 weeks. Weight, length and head circumference will be measured at baseline and 2, 4, 6, 8, 12 and 16 weeks of study entry. Formula volume will be recorded for a three-day period before each visit. Fecal samples will be obtained at baseline (convenience samples) and at week 16 for all subjects and analyzed for microbial populations. Buccal cheek cells of all infants, and mothers of breast fed infants, obtained by swab at week 16 will be genotyped for FUT2. Information on adverse events and new/change of medications will be collected at in person visits and by telephone interviews between in-person visits.
NUMBER OF SUBJECTS: It is estimated that approximately up to approximately 200 subjects will be enrolled in the formula groups to obtain up to approximately 65 evaluable per protocol subjects in each group. As non-randomized reference group of approximately 85 breastfed infants will be enrolled to obtain approximately 65 evaluable infants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Commercially availabel infant formula
sole source nutrition
Infant formula
Test formula with 2-FL
sole source nutrition
Infant formula
Breast Fed
sole source nutrition
Infant formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sole source nutrition
Infant formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy, term (37-42 weeks), appropriate for gestational age 2. At the time of enrollment:
* \< 14 days post-natal age at time of enrollment, either gender
* Exclusively formula fed or breastfed upon enrollment Subject must be in general good health and free from any clinically significant disease, condition, or illness that might interfere with the study evaluations. Prior labs must be present to confirm good health.
* Formula group infants: Mother has determined to use infant formula exclusively for feeding her baby through at least 16 weeks.
* Reference breastfed infants: Mother has determined to breastfeed exclusively through at least 16 weeks Written informed consent of parent/guardian, prior to any study related procedures being performed.
Exclusion Criteria
2\. Use of systemic medications by the subject that in the Investigator's opinion could impact evaluation of the subject's assessments.
3\. Discontinuation of exclusive breastfeeding by reference group (breastfed) infants.
4\. Fed with baby/solid foods on average more than once per day.
4 Days
36 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PBM Nutritionals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, United States
Qualmedica Research, LLC dba Pedia Research, LLC
Evansville, Indiana, United States
Advantage Clinical Trials
The Bronx, New York, United States
JBR Clinical Research
Salt Lake City, Utah, United States
PI-Coor Clinical Research, LLC
Burke, Virginia, United States
Hospital Clinica Bendana
San Pedro Sula, , Honduras
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRG-VA-17-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.